[go: up one dir, main page]

CU20120078A7 - Composiciones para tratar náusea y vómito centralmente mediados - Google Patents

Composiciones para tratar náusea y vómito centralmente mediados

Info

Publication number
CU20120078A7
CU20120078A7 CU2012000078A CU20120078A CU20120078A7 CU 20120078 A7 CU20120078 A7 CU 20120078A7 CU 2012000078 A CU2012000078 A CU 2012000078A CU 20120078 A CU20120078 A CU 20120078A CU 20120078 A7 CU20120078 A7 CU 20120078A7
Authority
CU
Cuba
Prior art keywords
vomiting
treat
compositions
náusea
centrally
Prior art date
Application number
CU2012000078A
Other languages
English (en)
Other versions
CU24048B1 (es
Inventor
Fabio Trento
Sergio Cantoreggi
Claudia Rossi
Roberta Cannella
Daniele S Bonadeo
Riccardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120078(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of CU20120078A7 publication Critical patent/CU20120078A7/es
Publication of CU24048B1 publication Critical patent/CU24048B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proveen composiciones y métodos para tratar o prevenir náusea y vómito en pacientes que pasan por quimioterapia, radioterapia o cirugía.
CU2012000078A 2009-11-18 2012-05-18 Composiciones para tratar náusea y vómito centralmente mediados CU24048B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US38270910P 2010-09-14 2010-09-14
PCT/IB2010/003106 WO2011061622A1 (en) 2009-11-18 2010-11-18 Compositions for treating centrally mediated nausea and vomiting

Publications (2)

Publication Number Publication Date
CU20120078A7 true CU20120078A7 (es) 2012-10-15
CU24048B1 CU24048B1 (es) 2014-12-26

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000078A CU24048B1 (es) 2009-11-18 2012-05-18 Composiciones para tratar náusea y vómito centralmente mediados

Country Status (40)

Country Link
US (1) US12042494B2 (es)
EP (3) EP2361090B1 (es)
JP (1) JP5890780B2 (es)
KR (1) KR101615108B1 (es)
CN (6) CN104856999A (es)
AP (1) AP3083A (es)
AU (1) AU2010320598B2 (es)
BR (1) BR112012011485B1 (es)
CA (1) CA2778301C (es)
CL (1) CL2012001276A1 (es)
CO (1) CO6551693A2 (es)
CR (1) CR20120216A (es)
CU (1) CU24048B1 (es)
CY (1) CY1118062T1 (es)
DK (2) DK2361090T3 (es)
DO (1) DOP2012000138A (es)
EA (1) EA026815B1 (es)
EC (1) ECSP12011907A (es)
ES (4) ES2559475T3 (es)
GE (1) GEP20156226B (es)
GT (1) GT201200156A (es)
HK (2) HK1214148A1 (es)
HR (3) HRP20140759T1 (es)
HU (1) HUE029677T2 (es)
IL (1) IL219576A (es)
LT (1) LT2722045T (es)
MA (1) MA33810B1 (es)
MX (1) MX2012005347A (es)
MY (1) MY159393A (es)
NI (1) NI201200090A (es)
NZ (1) NZ599439A (es)
PE (1) PE20121483A1 (es)
PH (1) PH12012500887A1 (es)
PL (3) PL2722044T3 (es)
PT (2) PT2361090E (es)
RS (2) RS55206B1 (es)
SI (2) SI2361090T1 (es)
SM (1) SMT201400112B (es)
TN (1) TN2012000170A1 (es)
WO (1) WO2011061622A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2361090B1 (en) 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
EP2744497B1 (en) * 2011-10-18 2016-04-06 Helsinn Healthcare SA Therapeutic combinations of netupitant and palonosetron
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
KR20250136946A (ko) 2015-03-04 2025-09-16 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN119074729A (zh) * 2017-11-17 2024-12-06 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
JP2021512869A (ja) * 2018-02-02 2021-05-20 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 経口製剤及びその使用
EP4268818A4 (en) * 2020-12-25 2024-06-19 Shanghai Shengdi Pharmaceutical Co., Ltd Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4633612A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL166272B1 (pl) 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
ES2226622T3 (es) 1999-02-24 2005-04-01 F. Hoffmann-La Roche Ag Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
HU230316B1 (hu) 2000-07-14 2016-01-28 F. Hoffmann-La Roche Ag N-oxidok, mint 4-fenil-piridin-származékok előgyógyszerei, eljárás és előállításukra és az ezeket tartalmazó gyógyszerkészítmények
CN1263446C (zh) 2000-12-14 2006-07-12 弗·哈夫曼-拉罗切有限公司 自乳化脂质基质(selm)
AU2003302072A1 (en) 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
RU2373936C2 (ru) * 2003-04-08 2009-11-27 Проджиникс Фармасьютикалз, Инк. Применение метилналтрексона для лечения синдрома раздраженного кишечника
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007096763A2 (en) 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
HRP20090341T1 (hr) * 2006-10-24 2009-07-31 Helsinn Healthcare S.A. Mekane kapsule koje sadrže palonosetron hidroksiklorid s poboljšanom stabilnosti i bioraspoloživosti
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
WO2009079587A2 (en) * 2007-12-18 2009-06-25 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
EP2361090B1 (en) 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting

Also Published As

Publication number Publication date
PL2361090T3 (pl) 2014-10-31
MY159393A (en) 2016-12-30
NZ599439A (en) 2014-06-27
HRP20170419T1 (hr) 2017-06-02
CN104856999A (zh) 2015-08-26
MA33810B1 (fr) 2012-12-03
KR20120101456A (ko) 2012-09-13
PL2722045T3 (pl) 2017-03-31
AP2012006278A0 (en) 2012-06-30
US20230263799A1 (en) 2023-08-24
SMT201400112B (it) 2014-11-10
AU2010320598B2 (en) 2016-06-16
PH12012500887A1 (en) 2016-08-26
CN107050455A (zh) 2017-08-18
GT201200156A (es) 2014-03-27
US12042494B2 (en) 2024-07-23
PL2722044T3 (pl) 2017-08-31
DK2722045T3 (en) 2016-10-24
JP5890780B2 (ja) 2016-03-22
DK2361090T3 (da) 2014-08-25
EP2722044B1 (en) 2017-01-04
EA201290356A1 (ru) 2012-12-28
CY1118062T1 (el) 2017-06-28
HRP20140759T1 (hr) 2014-10-24
CN107050455B (zh) 2020-09-29
CN106421793A (zh) 2017-02-22
KR101615108B1 (ko) 2016-05-12
AU2010320598A1 (en) 2012-06-14
TN2012000170A1 (en) 2013-12-12
ES2595077T3 (es) 2016-12-27
CN106512010A (zh) 2017-03-22
EA026815B1 (ru) 2017-05-31
ECSP12011907A (es) 2012-10-30
CA2778301C (en) 2016-06-14
CO6551693A2 (es) 2012-10-31
PT2361090E (pt) 2014-09-03
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
HUE029677T2 (hu) 2017-03-28
IL219576A0 (en) 2012-06-28
CN102655864A (zh) 2012-09-05
JP2013511507A (ja) 2013-04-04
CU24048B1 (es) 2014-12-26
HK1214147A1 (zh) 2016-07-22
EP2727590A1 (en) 2014-05-07
CA2778301A1 (en) 2011-05-26
EP2727590B1 (en) 2015-10-21
AP3083A (en) 2015-01-31
ES2559475T3 (es) 2016-02-12
WO2011061622A1 (en) 2011-05-26
CR20120216A (es) 2012-07-24
ES2623503T3 (es) 2017-07-11
EP2361090B1 (en) 2014-05-21
IL219576A (en) 2017-08-31
BR112012011485A2 (pt) 2018-04-03
NI201200090A (es) 2012-11-13
HK1214148A1 (zh) 2016-07-22
CN104856998A (zh) 2015-08-26
RS55206B1 (sr) 2017-01-31
CL2012001276A1 (es) 2012-12-07
LT2722045T (lt) 2016-09-26
MX2012005347A (es) 2012-08-03
SI2361090T1 (sl) 2014-09-30
PE20121483A1 (es) 2012-12-02
CN106421793B (zh) 2023-06-16
RS53491B1 (sr) 2015-02-27
ES2494015T3 (es) 2014-09-12
DOP2012000138A (es) 2012-11-15
PT2722045T (pt) 2016-10-18
SI2722045T1 (sl) 2017-02-28
HRP20161277T1 (hr) 2016-11-18
BR112012011485B1 (pt) 2021-06-29
GEP20156226B (en) 2015-01-26

Similar Documents

Publication Publication Date Title
CU24048B1 (es) Composiciones para tratar náusea y vómito centralmente mediados
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
MX2020002867A (es) Inhibidores de glucosilceramida sintasa.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
DK2252322T3 (da) Vaccinesammensætninger
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UY32546A (es) Composiciones y metodos para tratar cancer
MX389168B (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CY1115471T1 (el) Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης
TH149036B (th) การบำบัดรักษาแบบสารรวมซึ่งประกอบรวมด้วยตัวยับยั้ง sglt และตัวยับยั้ง dpp4
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO6721062A2 (es) Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek
ECSP13012736A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek

Legal Events

Date Code Title Description
FG Grant of patent